Greg joined Royalty Pharma in 2026. Prior to Royalty Pharma, Greg spent more than a decade at Memorial Sloan Kettering Cancer Center, most recently as Senior Vice President, Technology Development, where he led biotechnology startup efforts, technology transfer, monetization and business development. Earlier in his career, Greg was a Vice President at AllianceBernstein, where he led healthcare and life sciences investing for the firm’s venture capital fund. Previously, he served as a biotech analyst at Baker Brothers Investments and as a management consultant at McKinsey & Company, where he primarily worked with pharmaceutical and biotech companies. Greg received his MD from Yale School of Medicine and a BA in molecular biophysics and biochemistry from Yale College. He currently serves as a Lecturer in the Department of Economics at both Stanford University and Yale University, where he teaches courses on the economics and science of drug development.
